Share Price and Basic Stock Data
Last Updated: November 5, 2025, 4:26 pm
| PEG Ratio | -1.16 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Kwality Pharmaceuticals Ltd operates within the pharmaceuticals sector, focusing on the manufacture and distribution of various pharmaceutical products. The company’s revenue trajectory shows significant fluctuations, with reported sales of ₹456 Cr in FY 2022, followed by a decline to ₹251 Cr in FY 2023. However, the trend appears to reverse with FY 2024 sales reported at ₹307 Cr and ₹370 Cr for FY 2025 (TTM: ₹402 Cr). Quarterly sales also reflect this recovery, with the latest quarter, September 2023, reporting sales of ₹70 Cr, up from ₹56 Cr in September 2022. The company’s ability to rebound from previous downturns suggests a potential stabilization in its revenue streams, indicating a recovery phase. Despite the challenges faced, including a dip in FY 2023, the overall growth trajectory reflects positively on the strategic initiatives taken by the management to enhance operational efficiencies and market reach.
Profitability and Efficiency Metrics
Kwality Pharmaceuticals reported an operating profit margin (OPM) of 22% for the latest quarter, indicating a stable profitability profile, although it faced a low of 17% in March 2023. Over the fiscal years, the operating profit stood at ₹172 Cr in FY 2022, declining to ₹61 Cr in FY 2023, before rebounding to ₹80 Cr in FY 2025. The net profit margin for FY 2025 stood at 10.75%, reflecting a recovery from a challenging fiscal year. The company recorded a return on equity (ROE) of 16.2% and a return on capital employed (ROCE) of 18.2%, both of which are generally competitive within the pharmaceutical sector. However, the cash conversion cycle was reported at 209 days, indicating potential inefficiencies in inventory management and collection processes. This prolonged cycle may hinder liquidity and operational agility, necessitating management attention to enhance cash flow dynamics.
Balance Sheet Strength and Financial Ratios
Kwality Pharmaceuticals’ balance sheet demonstrates a total asset standing of ₹451 Cr as of March 2025, with total liabilities at ₹364 Cr, leading to a debt-to-equity ratio of 0.42. The company has reported reserves of ₹255 Cr, showcasing a solid capital base for future investments. Borrowings increased to ₹112 Cr, reflecting a strategic approach to leverage for growth, albeit with an interest coverage ratio of 8.33x, which is robust and indicates the company can comfortably meet its interest obligations. The price-to-book value ratio stands at 3.43x, suggesting that the stock is trading at a premium compared to its book value. Furthermore, with a current ratio of 1.67x, the company maintains a healthy liquidity position, which is generally favorable compared to industry norms. These financial metrics indicate a balanced approach towards growth and risk management, although the increasing borrowings may require careful monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Kwality Pharmaceuticals reveals a stable promoter holding of 54.82%, which has seen minor fluctuations over recent quarters. This level of promoter ownership typically instills confidence among investors regarding the management’s commitment to the company’s long-term vision. The public holding accounts for 44.86%, with foreign institutional investors (FIIs) not holding any stake, while domestic institutional investors (DIIs) have a minimal presence at 0.33%. The company reported an increase in the number of shareholders, rising from 4,198 in September 2022 to 10,115 by June 2025, indicating growing investor interest and confidence. This expanding shareholder base could suggest a positive outlook for the company as it regains momentum in its financial performance. However, the low institutional ownership may indicate a need for enhanced investor relations efforts to attract more institutional capital.
Outlook, Risks, and Final Insight
The outlook for Kwality Pharmaceuticals appears cautiously optimistic as the company transitions from a challenging fiscal year towards a recovery trajectory. Key strengths include a solid operational recovery evidenced by improving revenue and profitability metrics, alongside a robust capital structure that supports growth initiatives. However, risks remain, particularly concerning the extended cash conversion cycle and the rising borrowings that could impact financial flexibility if not managed prudently. The company must focus on improving operational efficiencies and inventory management to mitigate liquidity risks. Additionally, attracting institutional investors could enhance market perception and stability. Ultimately, if Kwality Pharmaceuticals can sustain its recovery while addressing these challenges, it may position itself favorably for future growth within the pharmaceuticals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Kwality Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 247/84.3 | 32.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,887 Cr. | 448 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.5 Cr. | 45.2 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.9 Cr. | 24.5 | 29.1/17.0 | 37.4 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,723.46 Cr | 1,194.35 | 54.38 | 197.30 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70 | 56 | 56 | 69 | 67 | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 |
| Expenses | 52 | 40 | 41 | 57 | 54 | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 |
| Operating Profit | 18 | 16 | 15 | 12 | 14 | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 |
| OPM % | 26% | 28% | 27% | 17% | 20% | 22% | 21% | 23% | 22% | 22% | 21% | 22% | 22% |
| Other Income | 0 | 1 | 0 | -15 | 0 | 0 | 1 | -7 | 0 | 0 | 1 | 1 | 0 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 |
| Depreciation | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 |
| Profit before tax | 14 | 11 | 10 | -10 | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 |
| Tax % | 25% | 20% | 28% | -24% | 25% | 24% | 21% | 28% | 25% | 33% | 25% | 24% | 30% |
| Net Profit | 11 | 9 | 7 | -7 | 5 | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 |
| EPS in Rs | 10.17 | 8.72 | 6.97 | -7.09 | 5.25 | 6.03 | 7.42 | 4.34 | 8.07 | 8.18 | 8.23 | 13.97 | 11.50 |
Last Updated: August 20, 2025, 7:55 am
Below is a detailed analysis of the quarterly data for Kwality Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 111.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Mar 2025) to 111.00 Cr., marking a decrease of 5.00 Cr..
- For Expenses, as of Jun 2025, the value is 87.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 90.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 3.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is 22.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Jun 2025, the value is 30.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 30.00%, marking an increase of 6.00%.
- For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 12.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 11.50. The value appears to be declining and may need further review. It has decreased from 13.97 (Mar 2025) to 11.50, marking a decrease of 2.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:58 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 52 | 76 | 95 | 137 | 165 | 138 | 261 | 456 | 251 | 307 | 370 | 402 |
| Expenses | 56 | 49 | 70 | 86 | 125 | 149 | 124 | 231 | 284 | 190 | 241 | 290 | 314 |
| Operating Profit | 4 | 4 | 6 | 9 | 12 | 15 | 14 | 29 | 172 | 61 | 67 | 80 | 87 |
| OPM % | 6% | 7% | 8% | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 22% | 22% | 22% |
| Other Income | 0 | 1 | 0 | 2 | 1 | 1 | 4 | 2 | 4 | -14 | -5 | 2 | 2 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 10 | 10 |
| Depreciation | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 18 | 19 |
| Profit before tax | 2 | 2 | 3 | 6 | 8 | 11 | 11 | 22 | 162 | 26 | 31 | 54 | 60 |
| Tax % | 47% | 29% | 39% | 41% | 38% | 31% | 24% | 29% | 26% | 24% | 24% | 26% | |
| Net Profit | 1 | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 | 24 | 40 | 43 |
| EPS in Rs | 0.95 | 1.32 | 1.89 | 3.31 | 4.51 | 7.28 | 8.12 | 14.86 | 115.70 | 18.76 | 23.11 | 38.44 | 41.88 |
| Dividend Payout % | 0% | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 100.00% | 50.00% | 66.67% | 60.00% | 0.00% | 87.50% | 700.00% | -84.17% | 26.32% | 66.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | -50.00% | 16.67% | -6.67% | -60.00% | 87.50% | 612.50% | -784.17% | 110.48% | 40.35% |
Kwality Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 22% |
| 3 Years: | -7% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 37% |
| 3 Years: | -31% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 73% |
| 3 Years: | 34% |
| 1 Year: | 19% |
| Return on Equity | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 28% |
| 3 Years: | 15% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 9:25 am
Balance Sheet
Last Updated: June 16, 2025, 11:48 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 13 | 15 | 18 | 21 | 21 | 28 | 37 | 52 | 172 | 192 | 216 | 255 |
| Borrowings | 6 | 8 | 13 | 19 | 26 | 28 | 35 | 41 | 54 | 90 | 98 | 112 |
| Other Liabilities | 12 | 10 | 17 | 27 | 41 | 40 | 53 | 65 | 106 | 71 | 74 | 72 |
| Total Liabilities | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 451 |
| Fixed Assets | 11 | 11 | 11 | 16 | 19 | 28 | 42 | 56 | 91 | 120 | 138 | 144 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 |
| Investments | 3 | 4 | 5 | 7 | 9 | 8 | 8 | 9 | 4 | 4 | 4 | 4 |
| Other Assets | 21 | 23 | 36 | 50 | 70 | 71 | 86 | 102 | 236 | 226 | 256 | 303 |
| Total Assets | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 451 |
Below is a detailed analysis of the balance sheet data for Kwality Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
- For Reserves, as of Mar 2025, the value is 255.00 Cr.. The value appears strong and on an upward trend. It has increased from 216.00 Cr. (Mar 2024) to 255.00 Cr., marking an increase of 39.00 Cr..
- For Borrowings, as of Mar 2025, the value is 112.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 98.00 Cr. (Mar 2024) to 112.00 Cr., marking an increase of 14.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 72.00 Cr.. The value appears to be improving (decreasing). It has decreased from 74.00 Cr. (Mar 2024) to 72.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 451.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 398.00 Cr. (Mar 2024) to 451.00 Cr., marking an increase of 53.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 144.00 Cr.. The value appears strong and on an upward trend. It has increased from 138.00 Cr. (Mar 2024) to 144.00 Cr., marking an increase of 6.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 303.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2024) to 303.00 Cr., marking an increase of 47.00 Cr..
- For Total Assets, as of Mar 2025, the value is 451.00 Cr.. The value appears strong and on an upward trend. It has increased from 398.00 Cr. (Mar 2024) to 451.00 Cr., marking an increase of 53.00 Cr..
Notably, the Reserves (255.00 Cr.) exceed the Borrowings (112.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -4.00 | -7.00 | -10.00 | -14.00 | -13.00 | -21.00 | -12.00 | 118.00 | -29.00 | -31.00 | -32.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 63 | 95 | 87 | 99 | 86 | 80 | 53 | 57 | 107 | 138 | 154 |
| Inventory Days | 58 | 61 | 54 | 72 | 54 | 34 | 94 | 38 | 97 | 310 | 187 | 167 |
| Days Payable | 58 | 40 | 61 | 67 | 79 | 52 | 96 | 58 | 63 | 117 | 106 | 112 |
| Cash Conversion Cycle | 41 | 85 | 89 | 92 | 74 | 68 | 78 | 33 | 91 | 300 | 219 | 209 |
| Working Capital Days | 60 | 35 | 41 | 21 | 19 | 21 | 43 | 25 | 62 | 120 | 103 | 100 |
| ROCE % | 12% | 11% | 15% | 19% | 19% | 21% | 18% | 26% | 97% | 18% | 16% | 18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 38.36 | 22.76 | 18.16 | 115.64 | 14.60 |
| Diluted EPS (Rs.) | 38.36 | 22.76 | 18.16 | 115.64 | 14.60 |
| Cash EPS (Rs.) | 55.99 | 41.61 | 33.00 | 125.89 | 20.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 253.70 | 213.74 | 191.08 | 172.50 | 56.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 254.47 | 214.51 | 191.85 | 173.27 | 57.68 |
| Revenue From Operations / Share (Rs.) | 356.77 | 296.03 | 241.93 | 439.64 | 252.51 |
| PBDIT / Share (Rs.) | 79.32 | 65.67 | 60.79 | 168.82 | 29.33 |
| PBIT / Share (Rs.) | 61.70 | 46.82 | 46.38 | 158.52 | 23.07 |
| PBT / Share (Rs.) | 52.18 | 29.97 | 24.65 | 155.71 | 20.50 |
| Net Profit / Share (Rs.) | 38.36 | 22.76 | 18.58 | 115.59 | 14.35 |
| NP After MI And SOA / Share (Rs.) | 38.40 | 22.93 | 18.67 | 115.64 | 14.60 |
| PBDIT Margin (%) | 22.23 | 22.18 | 25.12 | 38.39 | 11.61 |
| PBIT Margin (%) | 17.29 | 15.81 | 19.16 | 36.05 | 9.13 |
| PBT Margin (%) | 14.62 | 10.12 | 10.18 | 35.41 | 8.11 |
| Net Profit Margin (%) | 10.75 | 7.68 | 7.68 | 26.29 | 5.68 |
| NP After MI And SOA Margin (%) | 10.76 | 7.74 | 7.71 | 26.30 | 5.78 |
| Return on Networth / Equity (%) | 15.13 | 10.65 | 9.69 | 66.53 | 25.09 |
| Return on Capital Employeed (%) | 23.04 | 20.04 | 21.13 | 78.21 | 27.21 |
| Return On Assets (%) | 8.90 | 6.03 | 5.47 | 35.23 | 9.10 |
| Long Term Debt / Equity (X) | 0.05 | 0.08 | 0.13 | 0.11 | 0.30 |
| Total Debt / Equity (X) | 0.42 | 0.43 | 0.45 | 0.24 | 0.57 |
| Asset Turnover Ratio (%) | 0.87 | 0.82 | 0.72 | 1.79 | 1.73 |
| Current Ratio (X) | 1.67 | 1.60 | 1.65 | 1.75 | 1.35 |
| Quick Ratio (X) | 1.18 | 1.08 | 0.95 | 1.34 | 1.13 |
| Inventory Turnover Ratio (X) | 4.57 | 1.87 | 1.62 | 5.64 | 8.31 |
| Interest Coverage Ratio (X) | 8.33 | 6.56 | 10.48 | 60.05 | 11.39 |
| Interest Coverage Ratio (Post Tax) (X) | 5.03 | 3.96 | 6.95 | 42.11 | 6.57 |
| Enterprise Value (Cr.) | 997.78 | 515.35 | 400.57 | 630.81 | 85.72 |
| EV / Net Operating Revenue (X) | 2.70 | 1.68 | 1.60 | 1.38 | 0.32 |
| EV / EBITDA (X) | 12.12 | 7.56 | 6.35 | 3.60 | 2.82 |
| MarketCap / Net Operating Revenue (X) | 2.44 | 1.38 | 1.27 | 1.32 | 0.22 |
| Price / BV (X) | 3.43 | 1.90 | 1.60 | 3.34 | 0.96 |
| Price / Net Operating Revenue (X) | 2.44 | 1.38 | 1.27 | 1.32 | 0.22 |
| EarningsYield | 0.04 | 0.05 | 0.06 | 0.19 | 0.26 |
After reviewing the key financial ratios for Kwality Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For Diluted EPS (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For Cash EPS (Rs.), as of Mar 25, the value is 55.99. This value is within the healthy range. It has increased from 41.61 (Mar 24) to 55.99, marking an increase of 14.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 253.70. It has increased from 213.74 (Mar 24) to 253.70, marking an increase of 39.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 254.47. It has increased from 214.51 (Mar 24) to 254.47, marking an increase of 39.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 356.77. It has increased from 296.03 (Mar 24) to 356.77, marking an increase of 60.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 79.32. This value is within the healthy range. It has increased from 65.67 (Mar 24) to 79.32, marking an increase of 13.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 61.70. This value is within the healthy range. It has increased from 46.82 (Mar 24) to 61.70, marking an increase of 14.88.
- For PBT / Share (Rs.), as of Mar 25, the value is 52.18. This value is within the healthy range. It has increased from 29.97 (Mar 24) to 52.18, marking an increase of 22.21.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 38.40. This value is within the healthy range. It has increased from 22.93 (Mar 24) to 38.40, marking an increase of 15.47.
- For PBDIT Margin (%), as of Mar 25, the value is 22.23. This value is within the healthy range. It has increased from 22.18 (Mar 24) to 22.23, marking an increase of 0.05.
- For PBIT Margin (%), as of Mar 25, the value is 17.29. This value is within the healthy range. It has increased from 15.81 (Mar 24) to 17.29, marking an increase of 1.48.
- For PBT Margin (%), as of Mar 25, the value is 14.62. This value is within the healthy range. It has increased from 10.12 (Mar 24) to 14.62, marking an increase of 4.50.
- For Net Profit Margin (%), as of Mar 25, the value is 10.75. This value exceeds the healthy maximum of 10. It has increased from 7.68 (Mar 24) to 10.75, marking an increase of 3.07.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.76. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 10.76, marking an increase of 3.02.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.13. This value is within the healthy range. It has increased from 10.65 (Mar 24) to 15.13, marking an increase of 4.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.04. This value is within the healthy range. It has increased from 20.04 (Mar 24) to 23.04, marking an increase of 3.00.
- For Return On Assets (%), as of Mar 25, the value is 8.90. This value is within the healthy range. It has increased from 6.03 (Mar 24) to 8.90, marking an increase of 2.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 24) to 0.05, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.43 (Mar 24) to 0.42, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.82 (Mar 24) to 0.87, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.67. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.67, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 1.18, marking an increase of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.57. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 4.57, marking an increase of 2.70.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.33. This value is within the healthy range. It has increased from 6.56 (Mar 24) to 8.33, marking an increase of 1.77.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.03. This value is within the healthy range. It has increased from 3.96 (Mar 24) to 5.03, marking an increase of 1.07.
- For Enterprise Value (Cr.), as of Mar 25, the value is 997.78. It has increased from 515.35 (Mar 24) to 997.78, marking an increase of 482.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has increased from 1.68 (Mar 24) to 2.70, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 7.56 (Mar 24) to 12.12, marking an increase of 4.56.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 1.38 (Mar 24) to 2.44, marking an increase of 1.06.
- For Price / BV (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has increased from 1.90 (Mar 24) to 3.43, marking an increase of 1.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 1.38 (Mar 24) to 2.44, marking an increase of 1.06.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kwality Pharmaceuticals Ltd:
- Net Profit Margin: 10.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.04% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.13% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.03
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.4 (Industry average Stock P/E: 54.38)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Nagkalan, Amritsar Punjab 143601 | cs@kwalitypharma.com http://www.kwalitypharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramesh Arora | Managing Director |
| Mr. Aditya Arora | WholeTime Director & CFO |
| Mrs. Anju Arora | Whole Time Director |
| Mr. Ajay Kumar Arora | Whole Time Director |
| Mrs. Geeta Arora | Whole Time Director |
| Mr. Pankaj Takkar | Independent Director |
| Mr. Kartik Kapur | Independent Director |
| Mr. Prashanth Vellanki | Independent Director |
| Mr. Ravi Shanker Singh | Independent Director |
| Mr. Vinod Kumar Sharma | Independent Director |
FAQ
What is the intrinsic value of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd's intrinsic value (as of 05 November 2025) is 724.20 which is 19.35% lower the current market price of 898.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 932 Cr. market cap, FY2025-2026 high/low of 1,235/596, reserves of ₹255 Cr, and liabilities of 451 Cr.
What is the Market Cap of Kwality Pharmaceuticals Ltd?
The Market Cap of Kwality Pharmaceuticals Ltd is 932 Cr..
What is the current Stock Price of Kwality Pharmaceuticals Ltd as on 05 November 2025?
The current stock price of Kwality Pharmaceuticals Ltd as on 05 November 2025 is 898.
What is the High / Low of Kwality Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kwality Pharmaceuticals Ltd stocks is 1,235/596.
What is the Stock P/E of Kwality Pharmaceuticals Ltd?
The Stock P/E of Kwality Pharmaceuticals Ltd is 21.4.
What is the Book Value of Kwality Pharmaceuticals Ltd?
The Book Value of Kwality Pharmaceuticals Ltd is 256.
What is the Dividend Yield of Kwality Pharmaceuticals Ltd?
The Dividend Yield of Kwality Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Kwality Pharmaceuticals Ltd?
The ROCE of Kwality Pharmaceuticals Ltd is 18.2 %.
What is the ROE of Kwality Pharmaceuticals Ltd?
The ROE of Kwality Pharmaceuticals Ltd is 16.2 %.
What is the Face Value of Kwality Pharmaceuticals Ltd?
The Face Value of Kwality Pharmaceuticals Ltd is 10.0.